Elan Corporation, plc Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Apr 24 Calls Today's Calls

Call Details Elan Corporation, plc Earnings Conference Call (Q1 2008) Thu, Apr 24, 2008, 8:30 am Eastern Listen to the archived event audio About Elan Corporation, plc (NYSE:ELN) Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. It operates in two segments, Biopharmaceuticals and Elan Drug Technologies (EDT). The Biopharmaceuticals segment engages in research, development, and commercial activities primarily in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Crohn’s disease, severe chronic pain, and infectious diseases. It offers Tysabri, an alpha 4 integrin antagonist for the treatment of relapsing forms of multiple sclerosis; Prialt for the management of severe chronic pain in patients for whom intrathecal therapy is warranted; Maxipime, an injectable cephalosporin antibiotic to treat serious and/or life-threatening infections; and Azactam, an injectable antibiotic to treat pneumonia, post-surgical infections, and septicemia. This segment, through collaboration with Biogen Idec, Inc., develops and markets Tysabri as a treatment for Crohn’s disease. It also develops ELND005, a small molecule therapeutic that acts by breaking down and preventing the aggregation of beta amlyoid fibrils in collaboration with Transition Therapeutics, Inc. In addition, Biopharmaceuticals segment, through collaboration with Wyeth, develops beta amyloid immunotherapies, including AAB-001, AAB-002, and ACC-001, which are in various stages of development for the treatment of Alzheimer’s disease. The EDT segment engages in the development and manufacture of drug optimization technologies, including NanoCrystal technology that involves reducing crystalline drug to particles under 400 nanometers in size. This segment also offers a range of services, which include formulation development, clinical trial management, analytical development, clinical trial material manufacturing, product scale-up, product registration, and commercial manufacturing. It sells its products primarily to drug wholesalers worldwide. The company was founded in 1969 and is headquartered in Dublin, Ireland. More Info: Quote | Chart | Profile | Reports | Research | Msgs | Financials